journal contribution
posted on 2023-03-31, 03:26 authored by Chenxi Tian, Daniel Öhlund, Steffen Rickelt, Tommy Lidström, Ying Huang, Liangliang Hao, Renee T. Zhao, Oskar Franklin, Sangeeta N. Bhatia, David A. Tuveson, Richard O. Hynes Xenograft tumors knocked down and overexpressing AGRN, SERPINB5, and CSTB show expected protein expression changes.
Funding
STARR Cancer Consortium
Howard Hughes Medical Institute
Lustgarten Foundation
NCI
Koch Institute
Cold Spring Harbor
NIH
DOD
V Foundation
MIT
Swedish Research Council
Kempe Foundations
Swedish Society of Medicine
Västerbotten
Cancer Research Foundation in Northern Sweden
Swedish Foundation for International Cooperation in Research and Higher Education
Knut and Alice Wallenberg Foundation
Swedish Cancer Society
National Institute of Environmental Health Sciences
Ludwig Fund for Cancer Research
the Koch Institute's Marble Center for Cancer Nanomedicine
History
ARTICLE ABSTRACT
The prognosis for pancreatic ductal adenocarcinoma (PDAC) remains poor despite decades of effort. The abundant extracellular matrix (ECM) in PDAC comprises a major fraction of the tumor mass and plays various roles in promoting resistance to therapies. However, nonselective depletion of ECM has led to poor patient outcomes. Consistent with that observation, we previously showed that individual matrisome proteins derived from stromal cells correlate with either long or short patient survival. In marked contrast, those derived from cancer cells correlate strongly with poor survival. Here, we studied three cancer cell–derived matrisome proteins that are significantly overrepresented during PDAC progression, AGRN (agrin), SERPINB5 (serine protease inhibitor B5), and CSTB (cystatin B). Using both overexpression and knockdown experiments, we demonstrate that all three are promoters of PDAC metastasis. Furthermore, these proteins operate at different metastatic steps. AGRN promoted epithelial-to-mesenchymal transition in primary tumors, whereas SERPINB5 and CSTB enhanced late steps in the metastatic cascade by elevating invadopodia formation and in vivo extravasation. All three genes were associated with a poor prognosis in human patients and high levels of SERPINB5, secreted by cancer cells and deposited in the ECM, correlated with poor patient prognosis. This study provides strong evidence that cancer cell–derived matrisome proteins can be causal in promoting tumorigenesis and metastasis and lead to poor patient survival. Therefore, compared with the bulk matrix, mostly made by stromal cells, precise interventions targeting cancer cell–derived matrisome proteins, such as AGRN, SERPINB5, and CSTB, may represent preferred potential therapeutic targets.
This study provides insights into the biological roles of cancer cell–derived matrisome proteins in PDAC and supports the notion that these proteins are protumorigenic and better therapeutic targets.
